Glioblastoma is the most frequent and malignant brain tumor, characterized by an elevated
capacity for cellular proliferation and invasion. Recently, it was demonstrated that …

High-grade serous epithelial ovarian cancer (HGSOC) is the fifth leading cause of cancer
death in women and the first among gynecological malignancies. Despite an initial response …

Background Adding immunotherapy to first-line chemotherapy might improve outcomes for
patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin …

Background Invasive vulvar Paget's disease with over-expression of the human epidermal
growth factor receptor 2 (HER2) protein is potentially suitable for targeted therapy, especially …

Objective This open-label phase II clinical trial evaluated the antitumor activity and safety of
trabectedin in patients with advanced ovarian (OC) or uterine carcinosarcomas (UC) …

Cellular and humoral immunity are both required for SARS-CoV-2 infection recovery and
vaccine efficacy. The factors affecting mRNA vaccination-induced immune responses, in …

TP53 is the most frequently mutated gene in human cancers. Most TP53 genomic alterations
are missense mutations, which cause a loss of its tumour suppressor functions while …

Until recently, effective therapies for advanced endometrial cancer progressing to a platinum-
based combination were lacking. In this setting, immunotherapy with anti PD-1/PDL-1 …

Resistance to platinum chemotherapy regimens represents a major obstacle in the
successful treatment of epithelial ovarian cancer (EOC) patients. Among the molecular …

Rs3814113 is the single-nucleotide polymorphism (SNP) showing the strongest association
with high-grade serous ovarian carcinoma (HGSOC) incidence and is located in an …